Company Overview and News

 
Ferrovial SA ADR 2017 Q4 - Results - Earnings Call Slides

2018-03-01 seekingalpha
The following slide deck was published by Ferrovial SA ADR in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

1
Tata Motors appoints Hanne Sorensen as independent director

2018-01-03 moneycontrol
Tata Motors today announced appointment of Hanne Birgitte Sorensen, former CEO of Netherlands-based supply chain firm Damco, as an additional and independent director for a tenure of five years.
Upvote Downvote

 
ADVANCED SERIES TRUST Form N-Q

2015-12-01 sec.gov
Advanced Series Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES     Investment Company Act file number:      811-05186   Exact name of registrant as specified in charter:      Advanced Series Trust   Address of principal executive offices:      655 Broad Street, 17th Floor, Newark, New Jersey 07102   Name and address of agent for service:      Deborah A.
Upvote Downvote

 
AMERICAN BEACON FUNDS Form N-Q

2015-12-01 sec.gov
N-Q (9-30-15)     United States Securities and Exchange Commission Washington, DC 20549     FORM N-Q     QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-04984     AMERICAN BEACON FUNDS (Exact name of Registrant as specified in charter)     220 East Las Colinas Blvd., Suite 1200 Irving, Texas 75039 (Address of principal executive offices) (Zip code)     Gene L.
Upvote Downvote

 
PRUDENTIAL SERIES FUND Form N-Q

2015-12-01 sec.gov
The Prudential Series Fund UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES   Investment Company Act file number:    811-03623 Exact name of registrant as specified in charter:    The Prudential Series Fund Address of principal executive offices:    655 Broad Street, 17th Floor,    Newark, New Jersey 07102 Name and address of agent for service:    Deborah A.
Upvote Downvote

 
GOLDMAN SACHS TRUST Form N-Q

2015-11-30 sec.gov
Goldman Sachs Trust     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-05349 Goldman Sachs Trust (Exact name of registrant as specified in charter)     71 South Wacker Drive, Chicago, Illinois   60606   (Address of principal executive offices)   (Zip code)   Caroline Kraus, Esq.
Upvote Downvote

 
GOLDMAN SACHS TRUST Form EX-99.CERT

2015-11-30 sec.gov
Certifications Pursuant to Section 302 CERTIFICATIONS I, James A. McNamara, certify that:   1.   I have reviewed this report on Form N-Q of the Goldman Sachs Trust;   2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   3.
Upvote Downvote

 
GOLDMAN SACHS TRUST Form N-Q

2015-11-30 sec.gov
Goldman Sachs Trust     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-05349 Goldman Sachs Trust (Exact name of registrant as specified in charter)     71 South Wacker Drive, Chicago, Illinois   60606   (Address of principal executive offices)   (Zip code)   Caroline Kraus, Esq.
Upvote Downvote

 
NUVEEN INVESTMENT FUNDS INC Form EX-99.CERT

2015-11-30 sec.gov
Certifications CERTIFICATIONS I, Gifford R. Zimmerman, certify that:   1. I have reviewed this report on Form N-Q of Nuveen Investment Funds, Inc.;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   3.
Upvote Downvote

 
NUVEEN INVESTMENT FUNDS INC Form N-Q

2015-11-30 sec.gov
Nuveen Investment Funds, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-05309 Nuveen Investment Funds, Inc. (Exact name of registrant as specified in charter) Nuveen Investments 333 West Wacker Drive, Chicago, Illinois 60606 (Address of principal executive offices) (Zip code) Kevin J.
Upvote Downvote

 
JANUS INVESTMENT FUND Form N-Q

2015-11-30 sec.gov
Untitled Document OMB APPROVAL OMB Number: 3235-0578 Expires: January 31, 2016 Estimated average burden hours per response. . . . . . 10.5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-1879 Janus Investment Fund (Exact name of registrant as specified in charter) 151 Detroit Street, Denver, Colorado 80206 (Address of principal executive offic
Upvote Downvote

 
Brookfield Investment Funds Form N-Q

2015-11-30 sec.gov
brookfield_nq.htm   As filed with the Securities and Exchange Commission on November 27, 2015   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-Q     QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-22558 Brookfield Investment Funds (Exact name of registrant as specified in charter) Brookfield Place, 250 Vesey Street, 15th Floor, New York, NY 10281-1023 (Address of principal executive offi
Upvote Downvote

 
Virtus Total Return Fund Form EX-99.CERT

2015-11-30 sec.gov
Certification Pursuant to Section 302 Certification Pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act I, George R. Aylward, certify that:   1. I have reviewed this report on Form N-Q of Virtus Total Return Fund;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin
Upvote Downvote

 
Virtus Total Return Fund Form N-Q (Quarterly Schedule of Portfolio Holdings)

2015-11-30 sec.gov
Virtus Total Return Fund UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number            811-21680                                        Virtus Total Return Fund (Exact name of registrant as specified in charter)             101 Munson Street                                                              Greenfield, MA 01301-9668                      
Upvote Downvote

 
Best Asian Stock Ideas Today

2014-10-21 seekingalpha
1. This week - what to do day by day2. Recapping the first 5 of our Top trades into Xmas3. RRR cut may be as early as this week4. Top 10 trades into Xmas - #6 Anhui Conch 5. Aviate Events - UGL and DO
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 315437103